Heart Health

The heart beats about 100,000 times a day. It is the circulatory powerhouse, pumping oxygenated blood and circulating hormones throughout the body. A healthy heart is crucial to our healthspan and wellbeing, but when the heart is not functioning properly, the effects can be crippling. 

What problem do patients face?

An estimated 244.1 million people worldwide live with a cardiovascular disease. A typical heart attack involves the loss of approximately 1 billion cardiomyocytes and 2–3 billion other (mostly endothelial) myocardial cells. That’s a loss of nearly 4 billion various cardiac cells. This dramatic loss of cells leads to a significant negative impact on the length and quality of life[1,21,22]. With over 6.5 million people living with heart failure in the US alone, there is a void in vital patient care. Indeed, there are several medications that may help with cardiovascular disease, but none that reverse the extensive cardiovascular damage that has already been done. 

What is the solution?

Mesenchymal Stem Cells (MSCs) are regenerative cells that can provide substantial relief to suffering cardiac patients. These extraordinary cells create an anti-inflammatory environment around the heart and cardiovascular system, promoting tissue regeneration and improving heart muscle function. Studies utilizing these stem cells in patients have shown improved ventricular remodeling and cardiac metabolism, which directly translate into an overall improved quality of life. This is likely due to the fact that MSCs promote the formation of new blood vessels. Patients with poor vascularization may benefit from MSC therapy because of the creation of a more developed and complete circulatory network. MSCs can protect cardiac cells by stopping cell death, which in turn halts the progression of cardiac damage. These unique cells also stimulate proliferation and alteration of stem cells, which contribute to muscle regeneration [20]. MSCs are also capable of increasing ejection fraction, which is a key indicator of heart failure in patients. 

Our precision MSC therapy improves cardiac function at a cellular level. By halting cell degradation, increasing blood flow, and stimulating muscle regeneration, cardiac patients note a substantial improvement in quality of life and healthspan. Following our MSC therapy, patients experience: 

  • Significant decrease in discomfort and pain
  • Increased blood flow and oxygenation 
  • Decreased fatigue and reduced breathing difficulties
  • Increased stamina and endurance
  • Quicker healing and recovery
  • Improved function of other vital organs due to improved blood circulation

Hear about a real patient’s experience with REHEALTH

See if REHEALTH is Right for You

Cardiac patients now have the opportunity to not only stop progression of heart damage, but also reverse damage in order to improve levels of comfort and wellbeing. At REHEALTH, your health is our top priority. Our team of certified physicians and research staff design a therapeutic approach specific to your individual needs and condition. 

Join thousands of other patients who have experienced relief they never thought was possible. Schedule a free discovery call and start your journey to recovery today.

"*" indicates required fields



  1. Majka M, Sulkowski M, Badyra B, Musialek P. Concise review: mesenchymal stem cells in cardiovascular regeneration: emerging research directions and clinical applications. Stem Cells Trasl Med. 2017. 6(10):1859-67.
  2. Quevedo HC, Hatzistergos KE, Oskouei BM, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trinileage differenciation capacity. Proc Natl Acad Sci USA. 2009. 106:14022-7.
  3. Yeo RW, Lai RC, Zhang B, et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2013. 65:336-41.
  4. Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid AA, Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett. 2012. 147:47-54.
  5. Hubbard RE, O’Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med. 2009. 13(9B):3103-9.
  6. Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ study. Mech Ageing Dev. 2012. 133(6)456-66.
  7. Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009. 64(11):1183-9.
  8. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the health ABC study. J Gerontol A Biol Sci Med Sci. 2002. 57(5):M326-32.
  9. Serviddio G, Romano AD, Greco A, et al. Frailty syndrome is associated with altered circulating redox balance and increased markers of oxidative stress. Int J Immunopathol Pharmacol. 2009. 22(3):819-27.
  10. Tay L, Lim WS, Chan M, Ye RJ, Chong MS. The independent role of inflammation in physical frailty among older adults with mild cognitive impairment and mild-to-moderate Alzheimer’s disease. J Nutr Health Aging. 2016. 20(3):288-99.
  11. Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014. 6(5):526-39.
  12. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2012. 5:19.
  13. Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. Clin Geriatr Med. 2011. 27(1):79-87.
  14. Premer C, Blum A, Bellio MA, et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine. 2015. 2(5):467-75.
  15. Aso K, Tsuruhara A, Takagaki K, et al. Adipose-derived mesenchymal stem cells restore impaired mucosal immune responses in aged mice. PLoS ONE. 2016. 11(2): e0148185.
  16. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999. 284(5411):143-7.
  17. Hodgkinson CP, Bareja A, Gomez JA, et al. Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology. Circ Res. 2016. 118:95-107.
  18. Markel TA, Wang Y, Herrmann JL, et al. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physion Heart Circ Physiol. 2008. 295:H2308-14.
  19. Mirotsou M, Zhang Z, Deb A, et al. Secreted fizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell released paracrine factor mediating myocardial survival and repair.
  20. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010. 107:913-22.
  21. Reinecke H, Minami E, Zhu WZ, et al. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res. 2008. 103:1058-71.
  22. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics 2016 Update: A report from the American Heart Association. Circulation. 2016. 133:e38-60.
  23. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal tem cells with hematopoiesis supportive function and other potentials. Haematologica. 2006. 91(8):1017-26.
  24. Behjati M. Suggested indications of clinical practice guideline for stem cell therapy in cardiovascular diseases: a step wise appropiate use criteria for regeneration therapy. ARYA Atheroscler. 2013. 9(5):306-10.
  25. Collichia M, Jones DA, Beirne AM, et al. Umbilical cord-derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data. Cytotherapy. 2019. 1-12.